The aim of the study was to analyze the teachers attitudes towards smoke-free regulations in public places. The study population consisted of 348 teachers. Among the study participants the questionnaire was conducted including socio-demographic characteristic and smoking profile. Detailed information was collected about teachers' opinion on smoke-free public places. About 13% of study participants declared current daily tobacco smoking and 5% smoked occasionally. Almost all study participants (90%-93%) are in favor of smoking ban in offices, health and educational buildings and sport facilities. 83% supported smoking ban in workplaces. Most of the teachers were in favor of smoke-free restaurants (71%) but they were less likely to support smoke-free bars, pubs and clubs (55%). The percentage of teachers who supported total ban on smoking in the presence of pregnant women was 94% and in the presence of children 93%. About 27%of the study subjects did not accept the concept of raising taxes on tobacco. Total ban on tobacco advertising was accepted by 70% of teachers and support for pictorial warning on tobacco packages declared 75% of participants. About 45% of study population indicated that they noted other teachers smoked at school (where smoking is banned). For students such percentages were even higher (76%). It is important to strengthen educational and informational activities to increase public awareness on health consequences of active and passive smoking and the ways of elimination of such exposures.
Download full-text PDF |
Source |
---|
MAbs
January 2019
a Division of Biotherapeutics , National Institute for Biological Standards and Control (NIBSC), South Mimms , Potters Bar, Hertfordshire , UK.
Due to the increase in the number of infliximab products, the need for global harmonization of the bioactivity of this monoclonal antibody was recognized by the World Health Organization (WHO). In response, the National Institute for Biological Standards and Control (NIBSC) developed the first international standard (IS) for infliximab, which targets tumour necrosis factor (TNF). Each ampoule is assigned values of 500 IU of TNF neutralizing activity and 500 IU of binding activity.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!